ES2862175T3 - Receptor de tipo IGFR novedoso y usos del mismo - Google Patents

Receptor de tipo IGFR novedoso y usos del mismo Download PDF

Info

Publication number
ES2862175T3
ES2862175T3 ES16777913T ES16777913T ES2862175T3 ES 2862175 T3 ES2862175 T3 ES 2862175T3 ES 16777913 T ES16777913 T ES 16777913T ES 16777913 T ES16777913 T ES 16777913T ES 2862175 T3 ES2862175 T3 ES 2862175T3
Authority
ES
Spain
Prior art keywords
receptor
igfr
seq
insulin
antagonist
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
ES16777913T
Other languages
English (en)
Spanish (es)
Inventor
Heiko Lickert
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Helmholtz Zentrum München
Original Assignee
Helmholtz Zentrum München
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Helmholtz Zentrum München filed Critical Helmholtz Zentrum München
Application granted granted Critical
Publication of ES2862175T3 publication Critical patent/ES2862175T3/es
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2863—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for growth factors, growth regulators
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/72—Receptors; Cell surface antigens; Cell surface determinants for hormones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7088—Compounds having three or more nucleosides or nucleotides
    • A61K31/7105—Natural ribonucleic acids, i.e. containing only riboses attached to adenine, guanine, cytosine or uracil and having 3'-5' phosphodiester links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/115—Aptamers, i.e. nucleic acids binding a target molecule specifically and with high affinity without hybridising therewith ; Nucleic acids binding to non-nucleic acids, e.g. aptamers
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6872—Intracellular protein regulatory factors and their receptors, e.g. including ion channels
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/04—Endocrine or metabolic disorders
    • G01N2800/042—Disorders of carbohydrate metabolism, e.g. diabetes, glucose metabolism

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Organic Chemistry (AREA)
  • Biomedical Technology (AREA)
  • Genetics & Genomics (AREA)
  • General Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Biochemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biotechnology (AREA)
  • Hematology (AREA)
  • Zoology (AREA)
  • Diabetes (AREA)
  • Biophysics (AREA)
  • Cell Biology (AREA)
  • Urology & Nephrology (AREA)
  • Physics & Mathematics (AREA)
  • General Engineering & Computer Science (AREA)
  • Wood Science & Technology (AREA)
  • Microbiology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Endocrinology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Toxicology (AREA)
  • Plant Pathology (AREA)
  • Food Science & Technology (AREA)
  • Pathology (AREA)
  • Analytical Chemistry (AREA)
  • General Physics & Mathematics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Epidemiology (AREA)
  • Emergency Medicine (AREA)
  • Obesity (AREA)
ES16777913T 2015-09-07 2016-09-07 Receptor de tipo IGFR novedoso y usos del mismo Active ES2862175T3 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
LU92818 2015-09-07
PCT/EP2016/071126 WO2017042242A1 (en) 2015-09-07 2016-09-07 Novel igfr-like receptor and uses thereof

Publications (1)

Publication Number Publication Date
ES2862175T3 true ES2862175T3 (es) 2021-10-07

Family

ID=54337321

Family Applications (1)

Application Number Title Priority Date Filing Date
ES16777913T Active ES2862175T3 (es) 2015-09-07 2016-09-07 Receptor de tipo IGFR novedoso y usos del mismo

Country Status (8)

Country Link
US (1) US20190248905A1 (cg-RX-API-DMAC7.html)
EP (2) EP3896080A1 (cg-RX-API-DMAC7.html)
JP (3) JP7175760B2 (cg-RX-API-DMAC7.html)
CN (1) CN108026160A (cg-RX-API-DMAC7.html)
DK (1) DK3347376T3 (cg-RX-API-DMAC7.html)
ES (1) ES2862175T3 (cg-RX-API-DMAC7.html)
PL (1) PL3347376T3 (cg-RX-API-DMAC7.html)
WO (1) WO2017042242A1 (cg-RX-API-DMAC7.html)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES3013122T3 (en) 2018-04-27 2025-04-11 Aimed Bio Inc Magnetic-based biopanning method through attachment of magnetic bead to cell
CN113773400B (zh) * 2020-06-09 2023-08-18 宁波鲲鹏生物科技有限公司 一种门冬胰岛素衍生物及其应用
US20240343789A1 (en) * 2021-07-23 2024-10-17 Helmholtz Zentrum München - Deutsches Forschungszentrum für Gesundheit und Umwelt (GmbH) Igfr-l1 antibodies and uses thereof
WO2024218715A1 (en) 2023-04-19 2024-10-24 Btl Healthcare Technologies A.S. Culture media based on protein hydrolysate and a process for preparing thereof
US12668774B2 (en) 2023-10-12 2026-06-30 Btl Healthcare Technologies A.S. Product, system and method of cell cultivation

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4879231A (en) 1984-10-30 1989-11-07 Phillips Petroleum Company Transformation of yeasts of the genus pichia
GB8610600D0 (en) 1986-04-30 1986-06-04 Novo Industri As Transformation of trichoderma
EP0402226A1 (en) 1989-06-06 1990-12-12 Institut National De La Recherche Agronomique Transformation vectors for yeast yarrowia
US6075181A (en) 1990-01-12 2000-06-13 Abgenix, Inc. Human antibodies derived from immunized xenomice
US6150584A (en) 1990-01-12 2000-11-21 Abgenix, Inc. Human antibodies derived from immunized xenomice
US20020137890A1 (en) * 1997-03-31 2002-09-26 Genentech, Inc. Secreted and transmembrane polypeptides and nucleic acids encoding the same
US20070065448A1 (en) * 2005-07-06 2007-03-22 Applera Corporation Methods and compositions for treating diseases targeting MABA1
WO2010026473A2 (en) * 2008-09-04 2010-03-11 Oxford Biotherapeutics Ltd. Pta072 protein
WO2013151664A1 (en) * 2012-04-02 2013-10-10 modeRNA Therapeutics Modified polynucleotides for the production of proteins
WO2014124020A1 (en) 2013-02-05 2014-08-14 The Board Of Trustees Of The Leland Stanford Junior University Method for selecting agents that bind to transmembrane receptors in a conformationally-selective manner

Also Published As

Publication number Publication date
PL3347376T3 (pl) 2021-12-06
EP3347376A1 (en) 2018-07-18
JP2023015235A (ja) 2023-01-31
JP7807359B2 (ja) 2026-01-27
EP3896080A1 (en) 2021-10-20
CN108026160A (zh) 2018-05-11
WO2017042242A1 (en) 2017-03-16
JP2018528213A (ja) 2018-09-27
JP2025166096A (ja) 2025-11-05
DK3347376T3 (da) 2021-03-29
EP3347376B1 (en) 2021-01-06
JP7175760B2 (ja) 2022-11-21
US20190248905A1 (en) 2019-08-15

Similar Documents

Publication Publication Date Title
JP7807359B2 (ja) 新規なigfr様レセプター及びその使用
US8383602B2 (en) Use of TRIM72 as a target for muscle and heart enhancer
US20190269761A1 (en) Methods, compositions and screens for therapeutics for the treatment of synovial sarcoma
US20140303078A1 (en) Modulation of pancreatic beta cell proliferation
WO2018013053A9 (en) Methods of diagnosis and treatment of pre-eclampsia
JP6029019B2 (ja) 細胞接着阻害剤、細胞増殖阻害剤、並びに癌の検査方法および検査用キット
US11999776B2 (en) IGFR-like 2 receptor and uses thereof
US10188650B2 (en) Treatment of neurological disorders
US12583928B2 (en) Antibodies against IGFR-like receptor and uses thereof
US20150212086A1 (en) Diagnosis and Treatment of Brain Tumor
US20240317867A1 (en) Igfr-like 2 receptor and uses thereof
US20090170773A1 (en) Novel use of g-protein-conjugated receptor and ligand thereof
JP4451158B2 (ja) 転写制御シスエレメント及びそれに特異的に結合する転写調節因子並びにそれらの用途
JP4761812B2 (ja) マスクリン受容体およびその用途
US20150037251A1 (en) Mammalian homologues of flower, their use in cancer diagnostics, prevention and treatment
US20250353901A1 (en) Fusion proteins against sialosylated glycosphingolipids and sialated glycoproteins and uses thereof
EP2067480A1 (en) Musclin receptor and use thereof
WO2007108557A1 (ja) Ip3受容体結合タンパク質による細胞内標的分子の制御
US11136368B2 (en) Cancer treatment using CX26 blocking peptides
WO2015174441A1 (ja) 糖尿病の予防または治療剤のスクリーニング方法
WO2013059471A1 (en) Compositions and methods for treating leukemia